Illumina v. Ravgen (Fed. Cir. 23-1717): Appeal Closed in 17 Days
Illumina, Inc. brought an appellate challenge against Ravgen, Inc. at the U.S. Court of Appeals for the Federal Circuit over US7727720B2, a patent covering methods for the detection of genetic disorders. The appeal was filed and closed within a notably compressed 17-day window, with no verdict text in the available public record.
Illumina challenges Ravgen's prenatal diagnostics patent at Federal Circuit
On April 7, 2023, Illumina, Inc. filed an appeal at the U.S. Court of Appeals for the Federal Circuit (Case No. 23-1717) against Ravgen, Inc., the assignee of US7727720B2. The patent covers methods for the detection of genetic disorders — a technology domain central to non-invasive prenatal testing (NIPT) and liquid biopsy diagnostics. Illumina was represented by Naveen Modi of Paul Hastings, LLP; Ravgen was represented by Gabrielle E. Higgins.
The case closed on April 24, 2023 — just 17 days after filing. No Basis of Termination and no verdict text are recorded in the available public record. The specific circumstances and terms under which the appeal concluded are not disclosed in the available record.
A 17-day lifespan at the Federal Circuit is notably compressed relative to typical appellate timelines, which suggests early procedural resolution — though the precise mechanism is not determinable from the public record. What drove the rapid closure, and whether any agreement between the parties played a role, remains unknown from the available record.
See Complete Case & Patent Analysis →Filing to closed in 17 days
17 days — an unusually short Federal Circuit appeal window, suggesting early procedural resolution
US7727720B2 — Methods for detection of genetic disorders
Any company developing, manufacturing, or commercialising non-invasive prenatal testing products, cell-free DNA analysis platforms, or genetic disorder screening assays should treat US7727720B2 as a priority FTO target. Ravgen has demonstrated a pattern of active enforcement against major diagnostics and genomics companies, and the method claims of this patent are broad enough to capture a range of sample preparation, amplification, and analysis workflows.
Official order — verbatim text
No verdict text is recorded in the available public record for Case No. 23-1717. The absence of a disposition entry, combined with the 17-day case duration, suggests the appeal was resolved or terminated at an early procedural stage, though the specific mechanism is not determinable from the available record.
Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ILLUMINA, INC. | Company | /Search in Eureka ↗ |
| Defendant | Ravgen, Inc. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Naveen Modi | Attorney | Counsel for ILLUMINA, INC.Search in Eureka ↗ |
| Plaintiff law firm | Paul Hastings, LLP | Law Firm | Representing ILLUMINA, INC.Search in Eureka ↗ |
| Defendant counsel | Gabrielle E. Higgins | Attorney | Counsel for Ravgen, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the genetic disorder detection IP space
Forward-looking patent intelligence derived from Illumina v. Ravgen — surfacing portfolio trends, filing activity, and white-space opportunities in cfDNA and NIPT diagnostics.
Ravgen's cfDNA patent portfolio: scope and enforcement activity
US7727720B2 is part of a broader Ravgen portfolio covering non-invasive prenatal and genetic disorder detection methods. Understanding the full family scope — related applications, continuation filings, and international equivalents — is essential for any NIPT or cfDNA diagnostics company assessing IP risk exposure.
Ravgen patent familyFiling trends in non-invasive prenatal genetic analysis
Patent filing activity in NIPT, cfDNA sequencing, and chromosomal abnormality detection has accelerated across major genomics players including Illumina, Roche, and sequencing startups. Mapping the density and direction of filings in this space reveals competitive white space and potential conflict zones with Ravgen's asserted claims.
NIPT filing trendsIllumina's IP strategy in genetic diagnostics and sequencing
As the appellant in this Federal Circuit proceeding, Illumina's engagement with Ravgen's patent signals active portfolio management in the diagnostics space. Illumina holds a substantial IP estate in sequencing-by-synthesis and liquid biopsy applications — understanding how this portfolio intersects with NIPT method claims is valuable for competitors and partners alike.
Illumina IP strategyAdjacent R&D opportunities beyond Ravgen's claimed methods
Ravgen's claims focus on specific method steps for detecting genetic disorders from cell-free nucleic acids. White-space opportunity may exist in alternative detection modalities — including epigenetic profiling, methylation-based fetal fraction estimation, or long-read sequencing approaches — that may fall outside the literal scope of the asserted claims.
cfDNA white spaceSimilar Federal Circuit appeals in genetic diagnostics patent disputes
Explore related Federal Circuit appeals and district court actions involving cell-free DNA, non-invasive prenatal testing patents, and genetic disorder detection method claims.
What this case signals for the NIPT and genetic diagnostics IP landscape
Ravgen's US7727720B2 sits at the intersection of genomic sequencing and prenatal diagnostics — a high-stakes IP battleground with multiple active challengers.
US7727720B2 has attracted repeated appellate scrutiny — monitor its enforceability status
Illumina's Federal Circuit appeal, resolved in just 17 days, is consistent with ongoing industry pressure on Ravgen's foundational genetic disorder detection patents. Companies operating in NIPT, liquid biopsy, or cell-free DNA analysis should actively track the validity and enforceability status of this patent family.
Rapid appellate closure warrants attention to parallel proceedings and portfolio overlap
A 17-day Federal Circuit closure without a recorded disposition suggests the matter may have been resolved through procedural mechanisms not fully reflected in the public docket. IP teams should check for related IPR proceedings, district court actions, or licensing activity involving US7727720B2 and related Ravgen patents.
ILLUMINA v Ravgen — key questions answered
Case No. 23-1717 is a Federal Circuit appeal filed by Illumina, Inc. against Ravgen, Inc. on April 7, 2023. It concerns US7727720B2, a patent covering methods for the detection of genetic disorders. The appeal closed on April 24, 2023 — 17 days after filing. No Basis of Termination or verdict text is recorded in the available public record.
US7727720B2 is a Ravgen patent covering methods for detection of genetic disorders, positioned within the non-invasive prenatal testing and cell-free DNA diagnostics domain. It is commercially significant because its method claims are broad enough to implicate a wide range of NIPT and cfDNA-based diagnostic products. Ravgen has used this patent and related family members in an active enforcement programme against multiple major genomics and diagnostics companies.
The 17-day closure is notably compressed for a Federal Circuit appeal. The specific mechanism of closure is not recorded in the available public record — no Basis of Termination or verdict text has been entered. This timeline is consistent with an early procedural resolution, though the precise circumstances are not determinable from the public docket.
No merits disposition is recorded in the available public record for Case No. 23-1717. The case closed on April 24, 2023, but neither a Basis of Termination nor a verdict text has been entered. Whether the appeal was decided on the merits, dismissed procedurally, or resolved by another mechanism is not determinable from the available record.
Yes. Any company commercialising non-invasive prenatal testing products, cfDNA analysis platforms, or genetic disorder screening assays should treat US7727720B2 as a priority FTO target. Ravgen has an established enforcement history, and the patent's method claims are broad. An FTO analysis should cover the full Ravgen patent family, not just the asserted patent, to capture continuation and related filings.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.